Nxera pharma's partner neurocrine biosciences initiates phase 3 registrational program of nbi-1117568 as a potential treatment for adults with schizophrenia

Tokyo, japan and cambridge, uk, 1 may 2025 – nxera pharma co., ltd. (“nxera” or “the company”; tse 4565) today announces that its partner neurocrine biosciences inc. (“neurocrine”) has initiated a phase 3 registrational program to evaluate the efficacy, safety and tolerability of nbi-1117568 (nbi-'568), an investigational oral muscarinic m4 selective orthosteric agonist, as a potential treatment for schizophrenia. positive top-line data for the phase 2 clinical study in adults with schizophrenia were reported in august 2024.
NBIX Ratings Summary
NBIX Quant Ranking